English | 繁體

Search in the results

UM

Browse/Search Results:  1-10 of 293 Help

  Show only claimed items
Selected(0)Clear Items/Page:    Sort:
Exploring the mechanisms of Yuanhu Zhitong oral liquid for primary dysmenorrhea through network pharmacology, molecular docking, and molecular dynamics simulation Journal article
Zhang, Cheng Rui, Zhang, Dai Yan, Gao, Jin, Cao, Zhi Ming, Hu, Yuan Jia. Exploring the mechanisms of Yuanhu Zhitong oral liquid for primary dysmenorrhea through network pharmacology, molecular docking, and molecular dynamics simulation[J]. Reproductive and Developmental Medicine, 2024, 8(3), 138-150.
Authors:  Zhang, Cheng Rui;  Zhang, Dai Yan;  Gao, Jin;  Cao, Zhi Ming;  Hu, Yuan Jia
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:0.7/0.6 | Submit date：2024/10/10
Molecular Docking  Network Pharmacology  Primary Dysmenorrhea  Yuanhu Zhitong Oral Liquid  
Ganweikang extract protects hepatocytes from oxidative injury by activating Nrf2/HO-1 and MAPKs pathways Journal article
Xiao Linxuan, Zhao Mingming, Linghu Ke-Gang, Wu Guoping, Zhang Tian, Chen Chengyu, Guan Jianli, Cao Zhiming, HU YUANJIA, Yu Hua. Ganweikang extract protects hepatocytes from oxidative injury by activating Nrf2/HO-1 and MAPKs pathways[J]. Fitoterapia, 2024, 178, 106146.
Authors:  Xiao Linxuan;  Zhao Mingming;  Linghu Ke-Gang;  Wu Guoping;  Zhang Tian; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:2.5/2.7 | Submit date：2024/08/29
Acute Hepatic Injury  Ganweikang  Hepato-protection  Mapks  Nrf2/ho-1  
Big Data Analysis of Patents and Their Applications in Biomedical Research and Development Book chapter
出自: Exploring Computational Pharmaceutics ‐ AI and Modeling in Pharma 4.0:wiley, 2024, 页码:533 - 573
Authors:  Xu Jiaqi;  Yuan Jialu;  Cai hong;  HU YUANJIA
Favorite | TC[Scopus]:0 | Submit date：2024/08/29
BioInformatics In Patents  Biomedical Research  ChemInformatics In Patents  Data Mining  Patent Analysis  Pharmaceutics Patents  
Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials Journal article
Lyu, Liyang, Feng, Ye, Huang, Borong, Xu, Ren He, Hu, Yuanjia. Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials[J]. Nature Biotechnology, 2024, 42(4), 563-569.
Authors:  Lyu, Liyang;  Feng, Ye;  Huang, Borong;  Xu, Ren He;  Hu, Yuanjia
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:33.1/56.9 | Submit date：2024/05/02
Characteristics of clinical trials of new oncology drugs approved in China Journal article
Yang, Jing, Yang, Ji, Hu, Yuan Jia. Characteristics of clinical trials of new oncology drugs approved in China[J]. Cancer, 2024, 130(5), 671-682.
Authors:  Yang, Jing;  Yang, Ji;  Hu, Yuan Jia
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/05/16
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors  
Small molecule deoxynyboquinone triggers alkylation and ubiquitination of Keap1 at Cys489 on Kelch domain for Nrf2 activation and inflammatory therapy Journal article
Linghu, Ke-Gang, Zhang, Tian, Zhang, Guang-Tao, Lv, Peng, Zhang, Wenjun, Zhao, Guanding, Xiong, Shihong, Zhao, Mingming, Chen, Meiwan, HU YUANJIA, Zhang, Changsheng, Yu, Hua. Small molecule deoxynyboquinone triggers alkylation and ubiquitination of Keap1 at Cys489 on Kelch domain for Nrf2 activation and inflammatory therapy[J]. Journal of Pharmaceutical Analysis, 2024, 14(3), 401-415.
Authors:  Linghu, Ke-Gang;  Zhang, Tian;  Zhang, Guang-Tao;  Lv, Peng;  Zhang, Wenjun; et al.
Favorite | TC[WOS]:6 TC[Scopus]:9  IF:6.1/6.8 | Submit date：2024/01/02
Deoxynyboquinone  Anti-inflammation  Target  Keap1/nrf2  Alkylation  Ubiquitination  
Ruyong formula improves thymus function of CUMS-stimulated breast cancer mice Journal article
He, Bingqian, Guo, Wenqin, Shi, Rongzhen, Hoffman, Robert D., Luo, Qihan, Hu, Yuanjia, Guo, Jianli. Ruyong formula improves thymus function of CUMS-stimulated breast cancer mice[J]. Journal of Ethnopharmacology, 2024, 319(1), 117164.
Authors:  He, Bingqian;  Guo, Wenqin;  Shi, Rongzhen;  Hoffman, Robert D.;  Luo, Qihan; et al.
Adobe PDF | Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.8/4.8 | Submit date：2024/01/02
Ruyong Formula  Breast Cancer  Epithelial Mesenchymal Transition  Cums  Thymus Function  Jak2/stat3/pi3k Pathway  
Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials Journal article
Zhang, Daiyan, Lyu, Liyang, Han, Shuo, Xu, Jiaqi, Hu, Guang, Zhao, Qi, Hu Yuanjia. Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials[J]. International Immunopharmacology, 2024, 126, 111273.
Authors:  Zhang, Daiyan;  Lyu, Liyang;  Han, Shuo;  Xu, Jiaqi;  Hu, Guang; et al.
Adobe PDF | Favorite | TC[WOS]:0 TC[Scopus]:0  IF:4.8/5.0 | Submit date：2024/01/02
Car-t  Clinical Trials  Dual-target  Target Profiling  
Characteristics of clinical trials of new oncology drugs approved in China Review article
2023
Authors:  Jing Yang;  Ji Yang;  HU YUANJIA
Adobe PDF | Favorite | TC[WOS]:2 TC[Scopus]:2  IF:6.1/6.7 | Submit date：2024/01/02
Clinical Evidence  Drug Lag  Novel Anticancer Drugs  Pivotal Clinical Trials  Programmed Death-1 (Pd-1) Inhibitors  Programmed Death-ligand 1 (Pd-l1) Inhibitors  
Exploring potential therapeutic targets of DanShen and ChuanXiong for cardiovascular disease by node2vec algorithm. Conference paper
Zhang, Daiyan, HU YUANJIA. Exploring potential therapeutic targets of DanShen and ChuanXiong for cardiovascular disease by node2vec algorithm.[C], 2023.
Authors:  Zhang, Daiyan;  HU YUANJIA
Favorite |  | Submit date：2024/01/02